WuXi Biologics climbs 7% to 52-week high on mRNA vaccine boost
WuXi Biologics (2269.HK) climbed 7% in early Hong Kong trading on Thursday, rising to HK$50.05 and marking a fresh 52-week high.
The stock tracked a sector-wide advance in Hong Kong biotech names after Moderna and Merck released positive Phase III data for their mRNA melanoma vaccine, reigniting interest in the biopharmaceutical space.